RESUMEN
Study objectives: Narcolepsy type 1 (NT1) is a chronic sleep disorder characterized by loss of hypocretin-producing neurons. Increased NT1 incidence was observed in Sweden following mass-vaccination with Pandemrix®. Genetic association to HLA DQB1*06:02 implies an autoimmune origin, but target autoantigen remains unknown. Candidate autoantigens for NT1 have previously been identified in solid-phase immunoassays, while autoantibodies against conformation-dependent epitopes are better detected in radiobinding assays. The aims are to determine autoantibody levels against nine candidate autoantigens representing (1) proteins of the hypocretin transmitter system; Preprohypocretin (ppHypocretin), Hypocretin peptides 1 and 2 (HCRT1 and HCRT2) and Hypocretin receptor 2 (HCRTR2); (2) proteins previously associated with NT1; Tribbles homologue 2 (TRIB2), Pro-opiomelanocortin/alpha-melanocyte-stimulating-hormone (POMC/α-MSH) and Prostaglandin D2 Receptor DP1 (DP1); (3) proteins suggested as autoantigens for multiple sclerosis (another HLA DQB1*06:02-associated neurological disease); ATP-dependent Inwardly Rectifying Potassium Channel Kir4.1 (KIR4.1) and Calcium-activated chloride channel Anoctamin 2 (ANO2). Methods: Serum from post-Pandemrix® NT1 patients (n = 31) and their healthy first-degree relatives (n = 66) were tested for autoantibody levels in radiobinding assays separating autoantibody bound from free labelled antigen with Protein A-Sepharose. 125I-labelled HCRT1 and HCRT2 were commercially available while 35S-methionine-labelled ppHypocretin, HCRTR2, TRIB2, α-MSH/POMC, DP1, KIR4.1 or ANO2 was prepared by in vitro transcription translation of respective cDNA. In-house standards were used to express data in arbitrary Units/ml (U/ml). Results: All radiolabelled autoantigens were detected in a concentration-dependent manner by respective standard sera. Levels of autoantibodies in the NT1 patients did not differ from healthy first-degree relatives in any of the nine candidate autoantigens. Conclusions: None of the nine labelled proteins proposed to be autoantigens were detected in the radiobinding assays for conformation-dependent autoantibodies. The results emphasise the need of further studies to identify autoantigen(s) and clarify the mechanisms in Pandemrix®-induced NT1.
Asunto(s)
Autoanticuerpos/inmunología , Autoantígenos/inmunología , Vacunas contra la Influenza/efectos adversos , Vacunación Masiva/efectos adversos , Narcolepsia/inmunología , Adolescente , Adulto , Anciano , Niño , Femenino , Cadenas beta de HLA-DQ/genética , Humanos , Masculino , Persona de Mediana Edad , Narcolepsia/inducido químicamente , Ensayo de Unión Radioligante/métodos , Suecia , Adulto JovenRESUMEN
Injection site reactions (ISRs; redness, swelling and pain) commonly occur within 1-2 days after vaccination. After administration of toxoid vaccines including diphtheria toxoid, a later onset of ISRs has also been observed. As the serotype capsular polysaccharides in the 13-valent pneumococcal conjugate vaccine (PCV13) are conjugated to cross-reactive material 197 (CRM197), a nontoxic variant of diphtheria toxin, the onset of ISRs over 14 days was explored in 8 adult studies with 19 cohorts. Subjects received PCV13 with aluminum phosphate (AlPO4, n = 5667) or without AlPO4 (n = 304); 1097 subjects received 23-valent pneumococcal polysaccharide vaccine (PPSV23). Late ISRs with onset between days 6-14 were observed in 8/8 cohorts aged ≥65 years after PCV13 with AlPO4 (incidence across cohorts for redness, 2.3%-19.6%; swelling, 0.9%-10.8%; pain, 1.6%-10.0%) and in 1/1 cohort after PCV13 without AlPO4 (redness 10.5%; swelling 7.5%; pain 12.3%); and in 2/4 cohorts aged 50 to 64 years after PCV13 (redness 3.1%-4.8%; swelling 1.0%-3.2%; pain 3.7%-5%). Late ISRs were not generally observed in 1/1 cohort aged 18 to 49 years after PCV13; in 2/2 cohorts aged ≥53 years after PCV13 revaccination; and in 3/3 cohorts aged ≥60 years who received PPSV23, which does not contain CRM197. Post hoc analysis demonstrated numerically higher pneumococcal immune responses in subgroups with late ISRs versus those without. In conclusion, causality of late ISRs is likely multifactorial, with age and the PCV13 carrier protein CRM197 potentially associated. AlPO4, a vaccine adjuvant, did not appear causally related. Observations do not affect the favorable risk-benefit profile of PCV13.
Asunto(s)
Proteínas Bacterianas/efectos adversos , Reacción en el Punto de Inyección/epidemiología , Infecciones Neumocócicas/prevención & control , Vacunas Neumococicas/efectos adversos , Streptococcus pneumoniae/inmunología , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/efectos adversos , Adulto , Factores de Edad , Anciano , Compuestos de Aluminio/administración & dosificación , Compuestos de Aluminio/efectos adversos , Proteínas Bacterianas/administración & dosificación , Proteínas Bacterianas/inmunología , Estudios Clínicos como Asunto , Estudios de Cohortes , Humanos , Inmunización Secundaria/efectos adversos , Inmunización Secundaria/métodos , Incidencia , Reacción en el Punto de Inyección/inmunología , Vacunación Masiva/efectos adversos , Vacunación Masiva/métodos , Persona de Mediana Edad , Fosfatos/administración & dosificación , Fosfatos/efectos adversos , Infecciones Neumocócicas/inmunología , Infecciones Neumocócicas/microbiología , Vacunas Neumococicas/administración & dosificación , Vacunas Neumococicas/inmunología , Medición de Riesgo , Factores de Tiempo , Vacunas Conjugadas/administración & dosificación , Vacunas Conjugadas/efectos adversos , Vacunas Conjugadas/inmunología , Adulto JovenAsunto(s)
Vacunas contra Hepatitis B/efectos adversos , Sistemas de Registro de Reacción Adversa a Medicamentos , China , Bases de Datos Farmacéuticas , Industria Farmacéutica , Hepatitis B/prevención & control , Humanos , Lactante , Muerte del Lactante/etiología , Vacunación Masiva/efectos adversos , Programas Nacionales de Salud , Vacunas Sintéticas/efectos adversosRESUMEN
For decades, federal regulation of pharmaceutical drugs and medical devices has worked hand in hand with state tort claims to protect the health and safety of the American public. Now, a new trend toward preemption endangers this scheme. In recent years, the Supreme Court has given increasing deference to agency assertions about their preemptive authority and has found preemption in an increasing number of cases. In the process, the Supreme Court has preempted claims for medical device injuries and left claims for pharmaceutical harms in a precarious position. The elimination of common law claims for drug and device harms will leave holes in the FDA's regulatory scheme, endangering the health and safety of Americans. It will also prevent ordinary Americans from seeking compensation for their injuries--even those injuries caused by manufacturer malfeasance. This Article proposes that Congress create a no-fault compensation scheme for drugs and medical devices to close these gaps. Such a scheme could be both practical and politically possible, satisfying manufacturers, tort reformers, patients, and plaintiffs' lawyers alike.
Asunto(s)
Sistemas de Registro de Reacción Adversa a Medicamentos/organización & administración , Seguridad de Productos para el Consumidor/legislación & jurisprudencia , Industria Farmacéutica/legislación & jurisprudencia , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Legislación de Medicamentos , Seguridad del Paciente/legislación & jurisprudencia , Vigilancia de Productos Comercializados , Traumatismos del Nacimiento , Niño , Compensación y Reparación/legislación & jurisprudencia , Recolección de Datos , Aprobación de Recursos/legislación & jurisprudencia , Aprobación de Drogas/legislación & jurisprudencia , Gobierno Federal , Femenino , Regulación Gubernamental , Humanos , Recién Nacido , Formulario de Reclamación de Seguro/legislación & jurisprudencia , Revisión de Utilización de Seguros/legislación & jurisprudencia , Responsabilidad Legal , Mala Praxis , Vacunación Masiva/efectos adversos , Vacunación Masiva/legislación & jurisprudencia , Programas Nacionales de Salud/organización & administración , Embarazo , Medicamentos bajo Prescripción , Gobierno Estatal , Decisiones de la Corte Suprema , Traumatismos del Sistema Nervioso , Estados Unidos , United States Food and Drug Administration , Vacunación/efectos adversos , Vacunación/legislación & jurisprudenciaRESUMEN
BACKGROUND: In November 2009, a vaccination campaign against Influenza A (H1N1) was started in the Netherlands. The accelerated registration procedure of the vaccines used in this campaign and the use of these vaccines on a large scale indicated a need for real-time safety monitoring. OBJECTIVE: To describe the processing, analysing and performing of signal detection by the Netherlands Pharmacovigilance Centre (Lareb) on reports of adverse events following immunization (AEFI) with respect to the two pandemic influenza vaccines, Focetria® and Pandemrix®, used in the Netherlands. The secondary aim is to provide a summary of the results of the safety monitoring of both vaccines. STUDY DESIGN: Description of the process of collecting information and analysis of the safety monitoring of the pandemic vaccines during the vaccination campaign against H1N1 in the Netherlands. An observational study on adverse events following immunization (AEFIs) associated with vaccines used in this campaign was conducted. RESULTS: The use of a dedicated web form with predefined AEFIs enabled an efficient way of processing and analysing the reports, resulting in a close to real-time monitoring of the safety of the vaccines. From 1 November 2009 until 1 March 2010, 7534 reports concerning one or more AEFIs possibly related to the administration of both vaccines were received. 2788 of the reports related to Focetria® and 4746 of the reports related to Pandemrix®. The total time between receiving the reports and completion was longer for the serious reports (average 2.8 days) compared with the non-serious reports (average 0.8 days). The profile of the reported adverse events is comparable with the information provided in the Summary of Product Characteristics (SPC). Differences in reported AEFIs between both vaccines may be caused by bias and confounding due to the different populations for which these vaccines have been used. No signals of possible batch-related problems were detected for either vaccine. CONCLUSIONS: The method applied allowed for real-time monitoring for AEFIs during the mass vaccination campaign. The use of web-based forms, preferably with information on venue and used batch numbers, enabled an efficient monitoring of possible batch-related problems. No major safety issues occurred with respect to the type of reported AEFIs, or with the batches of either vaccine.